Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 657.80

+1.7%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Spartex who wrote (261)	2/2/1999 10:09:00 PM
From: Miljenko Zuanic	Read Replies (2) of 3557

QK: <<What is your rationale for favoring REGN to discontinue NT3 development "forever"? Being a diabetic, and still healthy, I'd love to see some progress on a drug that minimizes/reverses the onset of neuropathy, wouldn't you?>> I is not may rationale, it is REGN management perspective, and I agree. NT3 has side effects at higher doses, so to have needed therapeutic effects significant toxicity were observed. Also, other companies (pharma and bts) are looking seriously on this indication and they have advantage (small molecules). It is not tragic situation. NT3 may work in other indications. Constipation (niche market) seams as promising indication (BDNF and NT3). Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next